Repurposing of Kinase Inhibitors as Broad-Spectrum Antiviral Drugs
- PMID: 29148875
- PMCID: PMC5804095
- DOI: 10.1089/dna.2017.4033
Repurposing of Kinase Inhibitors as Broad-Spectrum Antiviral Drugs
Abstract
The high cost of drug development and the narrow spectrum of coverage typically provided by direct-acting antivirals limit the scalability of this antiviral approach. This review summarizes progress and challenges in the repurposing of approved kinase inhibitors as host-targeted broad-spectrum antiviral therapies.
Keywords: antiviral drugs; broad-spectrum antivirals; kinase inhibitors; repurposing.
Conflict of interest statement
No competing financial interests exist.
Figures
References
-
- Badia R., Angulo G., Riveira-Munoz E., Pujantell M., Puig T., Ramirez C., Torres-Torronteras J., Marti R., Pauls E., Clotet B., et al. (2016). Inhibition of herpes simplex virus type 1 by the CDK6 inhibitor PD-0332991 (palbociclib) through the control of SAMHD1. J Antimicrob Chemother 71, 387–394 - PMC - PubMed
-
- Chao S.H., Fujinaga K., Marion J.E., Taube R., Sausville E.A., Senderowicz A.M., Peterlin B.M., and Price D.H. (2000). Flavopiridol inhibits P-TEFb and blocks HIV-1 replication. J Biol Chem 275, 28345–28348 - PubMed
Publication types
MeSH terms
Substances
Grants and funding
LinkOut - more resources
Full Text Sources
Other Literature Sources
